Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue...

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...

Dyadic Expands Global Presence with Participation in Key Industry Events JUPITER, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the large-scale, efficient manufacturing of...

Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference JUPITER, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient,...